2020-08-21
2020年8月18日,苏州工业园区苏相合作区管理委员会与长风药业股份有限公司签约仪式在苏州相城区漕湖大厦举行。2020年6月,恒旭资本参与了长风药业最新一轮融资。
长风药业股份有限公司专注开发吸入给药技术,产品涉及哮喘、慢性阻塞性肺病、过敏性鼻炎等多个临床需求大的治疗领域,旨在打造优秀的综合性吸入制药企业,坚持高端制剂的仿制和创新产品同步发展,并成为制剂出口的先导企业,从而为全球提供优质产品。
公司2013年落户苏相合作区,已荣获江苏省民营科技企业、江苏省科技型中小企业、苏州市外国专家工作室、江苏省外国专家工作室、最具发展潜力创业企业、最佳科技创新奖、相城历年十佳落户企业、国际精英周落户企业 TOP100 等荣誉称号。
长风药业近期新动态不断,在6月份召开的苏州市“独角兽”企业发展大会上入选新一批苏州市“独角兽”培育企业名单;继1月份完成E轮6.3亿融资后,近期再次完成F轮3.6亿元融资,6个月内总计完成近10亿融资。
因企业生产需要,长风药业计划在苏相合作区打造集研发、生产、上市主体为一体的长风药业全球总部,建成后将主要研发吸入给药技术。产品主要用于治疗哮喘、慢性阻塞性肺病、鼻炎等疾病。
长风药业梁博士表示:
吸入制剂具有起效快、给药量小、便于携带等优势,因此市场需求量非常大。公司良好的背景、丰富的制药经验,以及政府的大力扶持等,都是长风深耕吸入制剂,不懈奋斗的源泉。新项目落户合作区后,长风将继续发挥自己的优势,力争未来五年内实现年销售数十亿元的目标。
恒旭资本团队认为:
吸入制剂行业市场空间大,具有进口替代空间,创始人是商业背景出身,长风的产品线布局合理且适合中国市场,公司未来在丰富产品线和海外销售端也有不错的预期。
上一篇:没有了
Change of Address Notice
Dear investors and partners,
With your ongoing care and support, Hengxu Capital has achieved significant development and progress since its establishment. In order to better meet the needs of our business operations, our office location will be relocated to 5F, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai(Map Link: https://j.map.baidu.com/b5/x7VK).
The new office space is conveniently located with excellent facilities, providing improved conditions for meetings, receptions, and work. This relocation will facilitate better communication and collaboration between Hengxu Capital and our partners, enhancing employee satisfaction and office efficiency, and laying a solid foundation for continued and rapid business development.
The new office has been officially in use since January 29, and our mailing address has been switched to the new location. Considering the approaching Chinese New Year, we will not hold a relocation ceremony at the moment but plan to invite you to visit and guide us at a suitable time in the future.
If you have any questions or concerns, please feel free to contact us. Our phone numbers and email addresses remain unchanged. Once again, we appreciate your support and understanding, and we look forward to creating a brighter future together.
Shanghai SAIC Hengxu Capital Co., Ltd.
Jan. 29, 2024